Alfresa Holdings stock forecast
Alfresa Holdings (ARHCF) Stock Forecast & Price Target
ARHCF Analyst Ratings
There are no analyst ratings in the last 3 months.
ARHCF Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Miyabi Yamakita | Jefferies | $15.83 | hold | 13.62%Upside | Reiterated | 07/28/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Miyabi YamakitaJefferies | HoldReiterated$15.83 | 07/28/26 | 13.62%Upside |
Best Analysts Covering Alfresa Holdings
Copying Google Medical - Distribution's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +8.50% per trade.
Copying Google Medical - Distribution's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +8.25% per trade.
Copying Google Medical - Distribution's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +8.80% per trade.
ARHCF Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 1 | 0 | 0 |
In the current month, ARHCF has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARHCF average Analyst price target in the past 3 months is ―.
ARHCF Financial Forecast
ARHCF Earnings Forecast
Next quarter’s earnings estimate for ARHCF is $0.52 with a range of $0.33 to $0.71. The previous quarter’s EPS was $0.21. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
ARHCF Sales Forecast
Next quarter’s sales forecast for ARHCF is $5.39B with a range of $5.37B to $5.40B. The previous quarter’s sales results were $5.00B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
